Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
SBFM 
Sunshine Biopharma Inc (SBFM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: SBFM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.65% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.19M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.73 | 52 Weeks Range 1.16 - 3.00 | Updated Date 12/10/2025 |
52 Weeks Range 1.16 - 3.00 | Updated Date 12/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -17.35% | Operating Margin (TTM) -10.55% |
Management Effectiveness
Return on Assets (TTM) -11.08% | Return on Equity (TTM) -25.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1717533 | Price to Sales(TTM) 0.18 |
Enterprise Value -1717533 | Price to Sales(TTM) 0.18 | ||
Enterprise Value to Revenue 39.48 | Enterprise Value to EBITDA -7.73 | Shares Outstanding 4905945 | Shares Floating 4554077 |
Shares Outstanding 4905945 | Shares Floating 4554077 | ||
Percent Insiders 2.94 | Percent Institutions 2.61 |
Upturn AI SWOT
Sunshine Biopharma Inc
Company Overview
History and Background
Sunshine Biopharma Inc. is a biopharmaceutical company focused on the research, development, and commercialization of novel drug candidates for the treatment of cancer and infectious diseases. The company was incorporated in 2004. Significant milestones include the progression of its lead drug candidates through preclinical and early clinical trials.
Core Business Areas
- Oncology Drug Development: Development of small molecule drugs targeting various cancers, with a focus on novel mechanisms of action.
- Infectious Disease Drug Development: Research and development of treatments for infectious diseases, including potential antiviral therapies.
Leadership and Structure
Sunshine Biopharma Inc. is led by a management team with experience in pharmaceutical research, development, and business operations. The organizational structure is typical of a biotechnology company, emphasizing research and development teams.
Top Products and Market Share
Key Offerings
- SBF-101 (Adva-27a): A novel anticancer drug candidate targeting DNA replication and cell division. Currently in clinical development for various cancers. Competitors include companies developing traditional chemotherapy agents and newer targeted therapies.
- SBF-211: A lead drug candidate for the treatment of COVID-19, being developed as an oral antiviral. Competitors include established pharmaceutical companies with approved COVID-19 treatments like Paxlovid.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development cycles, stringent regulatory approvals, and significant market potential for breakthrough therapies in oncology and infectious diseases. The market is highly competitive and driven by innovation.
Positioning
Sunshine Biopharma Inc. is positioned as a developer of novel therapeutics with the potential to address unmet medical needs in oncology and infectious diseases. Its competitive advantage lies in its proprietary drug candidates and focused research approach.
Total Addressable Market (TAM)
The TAM for oncology drugs is in the hundreds of billions of dollars globally, and the market for infectious disease treatments, particularly antivirals, is also substantial, fluctuating with global health events. Sunshine Biopharma Inc. aims to capture a segment of these markets with its innovative treatments.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates with novel mechanisms of action.
- Experienced research and development team.
- Focus on significant unmet medical needs in oncology and infectious diseases.
Weaknesses
- Limited historical revenue and profitability.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Reliance on external funding for research and development.
Opportunities
- Growing demand for innovative cancer treatments.
- Emerging infectious disease threats requiring new therapeutic solutions.
- Potential for strategic partnerships and collaborations.
Threats
- Intense competition from established pharmaceutical companies.
- High failure rates in drug development.
- Changes in regulatory landscape and reimbursement policies.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Merck & Co., Inc. (MRK)
- Gilead Sciences, Inc. (GILD)
Competitive Landscape
Sunshine Biopharma Inc. faces a highly competitive landscape dominated by large pharmaceutical companies with substantial R&D budgets, established market presence, and extensive distribution networks. Its advantage lies in developing novel therapies that could potentially disrupt existing treatment paradigms or address underserved patient populations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Sunshine Biopharma Inc. has been characterized by the progression of its pipeline through preclinical and early clinical development stages.
Future Projections: Future growth projections are contingent on the successful clinical development, regulatory approval, and eventual commercialization of its drug candidates. Analyst estimates are highly variable and dependent on early-stage data.
Recent Initiatives: Recent initiatives likely focus on advancing its lead drug candidates (e.g., SBF-101 and SBF-211) through clinical trials and securing funding for ongoing research and development activities.
Summary
Sunshine Biopharma Inc. is a preclinical and early-stage clinical biopharmaceutical company with promising drug candidates in oncology and infectious diseases. Its strengths lie in its novel research pipeline and experienced team, but it faces significant challenges related to funding, regulatory hurdles, and intense competition. Success hinges on the outcome of its clinical trials and ability to secure strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the U.S. Securities and Exchange Commission (SEC)
- Industry reports and market research databases
- Financial news and analysis platforms
Disclaimers:
This JSON output is for informational purposes only and does not constitute investment advice. Financial data and market positions are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sunshine Biopharma Inc
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2009-10-30 | Chairman, President & CEO Dr. Steve N. Slilaty Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 52 | Website https://sunshinebiopharma.com |
Full time employees 52 | Website https://sunshinebiopharma.com | ||
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.